VYVANSE

LOE Approaching

lisdexamfetamine dimesylate

NDAORALCAPSULE
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
28

Mechanism of Action

dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.

Clinical Trials (5)

NCT06847399Phase 2Recruiting

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Started Sep 2025
105 enrolled
Obesity and OverweightBinge Eating Disorder
NCT04866043N/ACompleted

Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder

Started Jun 2019
150 enrolled
Binge-eating Disorder
NCT02009163Phase 3Completed

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Started Jan 2014
418 enrolled
Binge Eating Disorder
NCT01890785Phase 1Completed

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

Started Jul 2013
30 enrolled
Healthy Volunteers
NCT01718483Phase 3Completed

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Started Nov 2012
383 enrolled
Binge Eating Disorder